[A18-43] Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 20.12.2018
Project no.:
A18-43
Commission:
Commission awarded on 28.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Adults infected with HIV-1
Treatment-naive adults and pretreated adults with indication for a treatment switch: added benefit not proven. Without indication for a treatment switch: added benefit not proven for men; indication of lesser benefit versus the appropriate comparator therapy for women.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-77 | Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Addendum to Commission A18-43 | Commission completed |
| A22-134 | Bictegravir/ emtricitabine/ tenofovir alafenamide (HIV infections in children and adolescents) – Benefit assessment according to § 35a SGB | Commission completed |
Federal Joint Committee (G-BA)
2018-12-20 A G-BA decision was published.